Nanobiotix completes dose escalation of of radioenhancer NBTXR3 study

Nanobiotix announced completion of the dose escalation part of a Phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer that cannot be treated by surgery inoperable , and has come back or recurrent, whom have previously been treated with definitive radiation therapy and are amenable to re-irradiation. The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center as part of an ongoing strategic collaboration with Nanobiotix. “NBTXR3 is designed as a product candidate with the potential to improve treatment outcomes for patients with cancer in any setting where radiotherapy is a part of the treatment regimen. While these patients experience different cancer types and are each faced with unique challenges, what they share is an urgent need for therapeutic innovation with the chance to make a difference,” said Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. “We believe the injection feasibility and favorable safety profile we have observed from the completed dose escalation part of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with inoperable, recurrent lung cancer and patients amenable to re-irradiation.”